Hanall Biopharma Launches New Probiotic Drug 'BioTop'

[Asia Economy Reporter Lee Gwan-joo] HanAll BioPharma announced on the 10th that it has expanded the product line of its original probiotic pharmaceutical 'BioTop,' which can be prescribed according to patient symptoms.

BioTop consists of 'BioTop-D,' a combination of three strains: Lactobacillus, Clostridium butyricum, and Bifidobacterium, and a high-dose product called 'BioTop-High.' It is indicated for diarrhea, constipation, loose stools, abdominal bloating, and abnormal intestinal fermentation. Recognized for faster symptom relief compared to single-agent formulations, it ranked among the top prescribed drugs in the antidiarrheal agent (A7F microbial antidiarrheal) category according to last year's Ubist data.

HanAll BioPharma has added 'Forte Capsule' and 'Dual Capsule' to BioTop-D and BioTop-High, respectively. The newly launched 'BioTop Forte Capsule' combines Clostridium butyricum, Bifidobacterium, and yeast. The Forte Capsule includes Saccharomyces boulardii, known to be minimally affected by stomach acid, bile, and antibiotics.

Additionally, the 'BioTop Dual Capsule' is a product combining two types of beneficial intestinal bacteria to help manage the gut through consistent intake. To this end, the ratio of Bifidobacterium and Clostridium butyricum has been increased compared to existing products.

Son Beom-gyu, Director of Sales Support at HanAll BioPharma, said, “We will continue to strive to expand treatment options for patients by adding new products with different formulations and ingredients.”